Wedbush Maintains Outperform on Oruka Therapeutics, Raises Price Target to $85
Benzinga Newsdesk 7 months ago
NewsPrice TargetAnalyst Ratings
Wedbush analyst Martin Fan maintains Oruka Therapeutics (NASDAQ:ORKA) with a Outperform and raises the price target from $45 to $85.
Wedbush analyst Martin Fan maintains Oruka Therapeutics (NASDAQ:ORKA) with a Outperform and raises the price target from $45 to $85.